{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004581","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.226359+00:00","generated_at":"2026-05-28T03:48:24.872572+00:00","sec_items":["2.02","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones","bullets":["Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.","CAN-2409 BLA submission for prostate cancer on track for Q4 2026; phase 3 data to be presented at upcoming scientific conference.","Updated overall survival data for CAN-2409 in pancreatic and lung cancer expected Q1 2025.","Phase 1b CAN-3110 overall survival data in recurrent high-grade glioma expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004581","json":"https://secwatch.observer/filing/0000950170-25-004581.json","markdown":"https://secwatch.observer/filing/0000950170-25-004581.md","text":"https://secwatch.observer/filing/0000950170-25-004581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/0000950170-25-004581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025004581/cadl-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:48:24.872572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}